Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Shanghai New World Co Ltd

600628:SHH

Shanghai New World Co Ltd

Actions
Consumer DiscretionaryConsumer Discretionary
  • Price (CNY)7.03
  • Today's Change0.09 / 1.30%
  • Shares traded7.97m
  • 1 Year change-2.63%
  • Beta0.4829
Data delayed at least 15 minutes, as of Nov 06 2024 07:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai New World Co Ltd is a China-based company mainly engaged in department store retail enterprises integrating modern department stores, tourism, leisure and entertainment comprehensive consumption. The Company operates its businesses through four segments. The Commercial segment is principally engaged in department store retail. The Pharmaceutical Industry segment is mainly engaged in the sales of various types of chinese medicinal materials, chinese patent medicines, western medicines, ginseng and antler supplements, nutritional health products and medical equipment. The Hotel Services segment is principally engaged in the operation of Radisson brand hotels managed by Radisson Hotel Group. The Company is also engaged in other businesses segment. The Company mainly operates its businesses in the domestic market.

  • Revenue in CNY (TTM)1.13bn
  • Net income in CNY45.48m
  • Incorporated1996
  • Employees1.20k
  • Location
    Shanghai New World Co LtdNo. 2-88, Nanjing West RoadSHANGHAI 200003ChinaCHN
  • Phone+86 2 163871786
  • Fax+86 2 163582185
  • Websitehttps://www.newworld-china.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Chengdu Olymvax Biopharmaceuticals Inc530.47m-8.70m4.31bn471.00--4.73--8.12-0.0219-0.02191.312.240.33010.36851.041,126,255.00-0.91433.17-1.284.6894.1993.00-2.777.441.67-0.53920.29159.82-9.3845.40-33.94--56.47--
Tibet Weixinkang Pharmaceutical Co Ltd1.26bn247.04m4.42bn701.0017.902.98--3.520.56770.56772.893.410.677816.415.561,791,483.0013.338.2017.0111.1353.4550.2019.6711.533.27--0.007559.11-5.4312.1320.9423.85-5.6138.96
Shanghai New World Co Ltd1.13bn45.48m4.49bn1.20k98.721.06--3.960.07030.07031.756.530.2013.9410.25942,735.100.79050.52421.050.724938.7733.703.932.711.57--0.115882.7533.39-16.40160.85-35.0053.61-25.42
Yabao Pharmaceutical Group Co Ltd2.83bn220.70m4.49bn4.14k20.411.52--1.590.30570.30573.864.100.73893.516.66683,686.805.112.826.383.9752.8559.206.924.192.04129.510.031343.747.05-0.057290.71-6.107.98-9.71
Zhejiang Shouxiangu Pharmaceuticl Co Ltd713.75m233.79m4.51bn1.14k19.072.02--6.321.191.193.6311.260.23670.71947.25624,455.807.7510.049.0911.6380.0183.6632.7528.293.48--0.209847.86-5.398.93-8.3918.7812.2317.13
Lionco Pharmaceutical Group Co Ltd277.20m-101.80m4.53bn475.00--5.29--16.34-0.144-0.1440.38281.190.18432.484.41583,571.30-6.770.7396-7.850.956241.7780.88-36.732.084.94-4.740.2409521.93-31.95-34.7922.65---33.18--
Pulike Biological Engineering Inc1.09bn101.68m4.57bn1.68k44.671.71--4.210.2960.2963.137.720.33732.482.65646,748.503.167.643.738.9660.4562.579.3617.852.51--0.008652.481.8415.553.995.1741.5818.47
ZhuZhou QianJin Pharmaceutical Co., Ltd3.73bn291.57m4.62bn5.34k15.751.92--1.240.69220.69228.845.690.8353.8810.04699,947.808.258.9915.1216.2145.0644.599.8810.032.18--0.0968.27-5.662.685.534.64-1.06-2.64
Shanghai OPM Biosciences Co Ltd287.29m38.09m4.63bn285.00121.222.20--16.100.33240.33242.5218.310.12592.233.591,008,039.001.634.341.694.6557.2858.3112.9323.4017.02--0.031145.38-17.4148.34-48.72--6.09--
Data as of Nov 06 2024. Currency figures normalised to Shanghai New World Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

0.33%Per cent of shares held by top holders
HolderShares% Held
China Universal Asset Management Co., Ltd.as of 30 Jun 20241.15m0.18%
The Vanguard Group, Inc.as of 30 Sep 2024479.00k0.07%
Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 2024234.20k0.04%
Wanjia Asset Management Co., Ltd.as of 30 Jun 2024109.90k0.02%
Xinyuan Asset Management Co., Ltd.as of 30 Jun 202469.90k0.01%
China Southern Asset Management Co., Ltd.as of 30 Jun 202455.50k0.01%
Nuode Asset Management Co., Ltd.as of 30 Jun 202428.84k0.00%
Springs Fund Management Co. Ltd.as of 30 Jun 202413.80k0.00%
Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 30 Jun 20249.60k0.00%
Harvest Fund Management Co., Ltd.as of 30 Jun 20244.90k0.00%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.